NCT01273922View on ClinicalTrials.gov

Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

December 31, 2011

Conditions
Staphylococcal InfectionsCandidiasis
Interventions
BIOLOGICAL

NDV-3 investigational vaccine

Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly

Trial Locations (1)

58104

Cetero, Fargo

Sponsors
All Listed Sponsors
collaborator

Cetero Research, San Antonio

NETWORK

collaborator

United States Department of Defense

FED

lead

NovaDigm Therapeutics, Inc.

INDUSTRY

NCT01273922 - Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida | Biotech Hunter | Biotech Hunter